Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Perceptive Advisors Buys 4.0 Million Shares Of Amicus Therapeutics Inc. (FOLD)

Perceptive Advisors, managed by Joseph Edelman, is bullish on Amicus Therapeutics Inc. (NASDAQ:FOLD). In a new filing with the U.S. Securities and Exchange Commission, Perceptive Advisors revealed that it has purchased 4.0 million shares of the company in two transactions at an average price of $3.5 for an aggregate price of $14.0 million. Currently, the fund owns 12.34 million shares of common stock of Amicus Therapeutics Inc. (NASDAQ:FOLD), up from 8.34 million shares reported previously.

Amicus Therapeutics

Amicus Therapeutics Inc. (NASDAQ:FOLD) is a biopharmaceutical engaged in developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases.

On Monday, the company provided updates and detailed the statistical analysis plan for its second Phase 3 study of the oral small molecule pharmacological chaperone migalastat HCl monotherapy for Fabry patients with amenable mutations. “The 18-month primary treatment period is now complete and top-line data from Study 012 are expected in the third quarter of 2014. If successful, Study 012 will trigger the process for European regulatory approval of migalastat as a monotherapy for Fabry patients with amenable mutations,” the company said in a statement.

For the first quarter of 2014, the company reported net loss of $15.9 million, or $0.25 per share, compared to a net loss of $17.5 million, or $0.35 per share, in the same quarter of 2013. It reduced total operating expenses to $16.1 million, compared to $17.3 million for the first quarter 2013 due to decreases in personnel and contract research costs. For full-year 2014, the company continues to expect net cash spend between $54 million and $59 million. The current cash position is projected to fund operations into the second half of 2015.

Amicus Therapeutics Inc. (NASDAQ:FOLD) has market cap of $256.7 million. Shares of the company jumped by 19.46% on Tuesday, hitting $3.99. It has a 52 week high of $4.30 and a 52 week low of $1.77. Analysts have the consensus average target price of $4.00 for the stock.

Other largest shareholders of the company include Jeremy Green’s Redmile Group, which owns around 8.50 million shares, and William Leland Edwards’ Palo Alto Investors, which holds 3.97 million shares.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!